Kyowa Kirin, Inc.
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1949-01-01
- Employees
- 7.1K
- Market Cap
- $12B
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT05027646
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
- Conditions
- Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04745234
- Locations
- 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇪🇸Hospital del Mar, Barcelona, Spain
Expanded Access for KHK2455
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Registration Number
- NCT04321694
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04190654
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Pinnacle Clinical Research, San Antonio, Texas, United States
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04147910
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
- Conditions
- Leukemia/LymphomaATLLCutaneous T Cell Lymphoma
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04014374
- Locations
- 🇺🇸
CIBMTR, Milwaukee, Wisconsin, United States
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03915405
- Locations
- 🇺🇸
Kyowa Research Site USA005, Iowa City, Iowa, United States
🇺🇸Kyowa Research Site USA 009, Houston, Texas, United States
🇪🇸Kyowa Research Site ESP003, Barcelona, Spain
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT03703102
- Locations
- 🇯🇵
Kyowa Investigational Site JP-25, Shimane, Japan
🇺🇸Kyowa Investigational Site US-02, Dallas, Texas, United States
🇩🇪Kyowa Investigational Site GE-14, Berlin, Germany
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
- Conditions
- X-Linked Hypophosphatemia
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02915705
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02867007